Meanwhile in a down market Disc up 1.65% to a market cap in...

Meanwhile in a down market Disc up 1.65% to a market cap in Australian Dollars of over $2.42 Billion (more than 3 times CUV). This is despite loss making Disc just hoping that one day in many years they will enter the EPP market with their lead product. That would be the EPP market in which Clinuvel currently has an absolute monopoly and is printing cash and will have that monopoly for many years to come (~4-5 years IMO).

I am always impressed how Disc is so much more adept at attracting investor interest than Clinuvel, sure we get daily interest from Short sellers which the company declines to mention. The company did mention in the latest newsletter that a single institution did buy a lot of shares in one month and that was enough to drive the share price over $40 (sep 21)- would be nice if they could get another one or two to do that occasionally - or at least implement a share buyback to protect shareholder interests as shorters have clearly got control over the ongoing share price here and that one institution who bought many shares shows how it effectively it will work. No need to mention most analyst price targets are mid $20s for CUV on EPP alone and one is about $50 because they took the phase 3 trial running in blockbuster Vitiligo into account.

It would be bloody funny to see Disc take-over CUV, the loss making startup taking over the established and very profitable incumbent in the market they only have dreams of entering. Certainly makes sense from their perspective, immediately cash flow neutral/positive, risk massively reduced, ability to spend more, competition eliminated, immediate FDA approved drug and indication, pick up a phase 3 into a much bigger indication and a network of centres and their share price would probably just go up higher. Would be one of the greatest corporate moves in history.

Anyway I'm sure our highly paid management team will dig us out of this mess any day now.

All IMO DYOR